The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Oncotype DX in BRCA-associated vs. sporadic breast cancers: Differences based on germline mutation status and potential implications for adjuvant systemic therapy (AST).

Payal Deepak  Shah

Stock and Other Ownership Interests  - Amgen, Johnson & Johnson, Novo Nordisk; Johnson & Johnson, Novartis, Novo-Nordisk, Pfizer, Merck (I)

Consulting or Advisory Role - Novartis

Sujata  Patil

No Relationships to Disclose

Maura N.  Dickler

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; Genentech/Roche; Merrimack; Novartis; Pfizer; Syndax

Research Funding - Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst)

Kenneth  Offit

No Relationships to Disclose

Clifford A.  Hudis

Other Relationship - Breast Cancer Research Foundation

Mark E.  Robson

Consulting or Advisory Role - AstraZeneca; Bayer; Biomarin; McKesson; Pfizer

Research Funding - AbbVie (Inst); AstraZeneca (Inst); Myriad Genetics (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Biomarin